Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know
Viking Therapeutics, Inc. (VKTX) closed at $33.98 in the latest trading session, marking a +1.43% move from the prior day.
Zacks Investment Research9/3/2026Positive
VKTX
Viking Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$4.07B
P/E Ratio
—
EPS
$-4.67
Beta
0.68
52W High
$43.15
52W Low
$22.96
50-Day MA
$35.43
200-Day MA
$33.50
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
-0.03
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -88.80% |
| Return on Assets | -51.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.50 |
| Price-to-Book | 9.71 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -71.64 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $116.65M |
| Float | $113.73M |
| % Insiders | 3.10% |
| % Institutions | 66.11% |
Historical Volatility
HV 10-Day
40.94%
HV 20-Day
45.76%
HV 30-Day
42.40%
HV 60-Day
53.15%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($92.39 target)
5
Strong Buy13
Buy2
HoldLatest News
Viking Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Annual Cantor Global Health Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the Bernstein 3rd Annual Healthcare Forum in September.
PRNewsWire9/2/2026Neutral
Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next.
VK2735 is Viking's lead candidate for obesity with dual-formulation potential. Major trial results are years away, so volatility is likely, but upcoming trial data could shift sentiment in the near term.
The Motley Fool8/30/2026Negative
Why Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research8/28/2026Positive
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?
Lilly's strong Q2, GLP-1 momentum and broad pipeline support growth, but valuation and rising competition remain key risks.
Zacks Investment Research8/17/2026Positive
VKTX Q2 Earnings Beat Estimates Despite Surge in R&D Costs
Viking Therapeutics beats second-quarter loss estimates as it advances late-stage obesity studies despite sharply higher R&D spending tied to its expanding pipeline.
Zacks Investment Research7/30/2026Positive
Viking Therapeutics, Inc. (VKTX) Q2 2026 Earnings Call Transcript
Viking Therapeutics, Inc. (VKTX) Q2 2026 Earnings Call Transcript
Seeking Alpha7/30/2026Neutral
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in Obesity Fully Enrolled and Advancing -- -- Oral Phase 3 VK2735 Trial Initiation Expected 4Q26 -- -- VK2735 Maintenance Dosing Data Expected 3Q26 -- -- Phase 1 Study of Amylin Agonist VK3019 Underway -- -- Strong Quarter-End Cash Position of $502 Million -- SAN DIEGO, July 29, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2026, and provided an update on its clinical pipeline and other corporate developments.
PRNewsWire7/29/2026Neutral
3 Biotech Stocks With Massive Upside to Buy Before August Starts
Biotech is setting up as one of the more interesting risk-on trades heading into the back half of 2026.
24/7 Wall Street7/29/2026Positive
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?
Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.
Zacks Investment Research7/28/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VKTX and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026